EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression

Mingxu Xie, Kai Yuan, Yongxin Zhang, Yating Zhang, Ruyi Zhang, Jiuhe Gao, Wenchao Wei, Lanping Jiang, Tianhui Li, Yanqiang Ding, Luyao Wang, Yufeng Lin und 2 weitere

Cancer Cell · 2025-10 · 43 (10) · 1885-1901.e10

DOI: 10.1016/j.ccell.2025.07.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-10. Verfasst von Mingxu Xie und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Healt…. Hauptthemen laut MEDLINE: Clostridium butyricum, Colorectal Neoplasms, Probiotics, Interleukin-6. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Innovation and Technology Fund, National Key Research and Development Program of China Stem Cell and Translational Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most colorectal cancer (CRC) patients do not respond to immune checkpoint blockade (ICB) therapy. Here, we identify Clostridium butyricum as a probiotic that boosts anti-PD-1 efficacy in CRC. In orthotopic allografts of microsatellite instability-high (MSI-H) and microsatellite stable (MSS) CRC, C. butyricum potentiates tumor suppressive effect of anti-PD-1, which is verified in AOM/DSS-induced CRC and germ-free mice. Single-cell RNA-seq reveals that C. butyricum activates cytotoxic CD8+ T lymphocytes (CTLs) and impairs tumor-associated macrophages (TAMs), especially in conjunction with anti-PD-1. Mechanistically, C. butyricum surface protein secD binds to CRC cell receptor glucose-regulated protein 78 (GRP78), which inactivates GRP78 and PI3K-AKT-NF-κB pathway, leading to reduced secretion of interleukin (IL)-6, an immunosuppressive cytokine that blunts CTLs and induces TAMs. Translational impact of C. butyricum in boosting anti-PD-1 efficacy is validated in huCD34+ humanized mice and autologous patient-derived CRC organoids-CTLs co-culture system. To summarize, C. butyricum is a promising adjuvant to augment ICB therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridium butyricumColorectal NeoplasmsProbioticsInterleukin-6Immune Checkpoint InhibitorsAnimalsMiceHumansEndoplasmic Reticulum Chaperone BiPProgrammed Cell Death 1 ReceptorMice, Inbred C57BLCell Line, TumorTumor-Associated Macrophages

Stichwörter der Autor:innen

Clostridium butyricumcolorectal cancercytotoxic CD8(+) T cellsimmune checkpoint blockadeimmunotherapyintratumoral bacteriapatient-derived autologous organoids and TILs cocultureprobiotics

Substanzen

Interleukin-6Endoplasmic Reticulum Chaperone BiPHSPA5 protein, humanHspa5 protein, mouseImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University o…
  • Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Förderung

  • National Key Research and Development Program of China
  • Innovation and Technology Fund
  • National Key Research and Development Program of China Stem Cell and Translational Research
  • Chinese University of Hong Kong

Zitieren

APA

Xie, M., Yuan, K., Zhang, Y., Zhang, Y., Zhang, R., Gao, J., Wei, W., Jiang, L., Li, T., Ding, Y., Wang, L., Lin, Y., Wong, C. C., & Yu, J. (2025). Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer Cell, 43(10), 1885-1901.e10. https://doi.org/10.1016/j.ccell.2025.07.012

Vancouver

Xie M, Yuan K, Zhang Y, Zhang Y, Zhang R, Gao J, et al. Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer Cell. 2025;43(10):1885-1901.e10. doi:10.1016/j.ccell.2025.07.012

BibTeX
@article{Xie2025,
  author = {Xie, Mingxu and Yuan, Kai and Zhang, Yongxin and Zhang, Yating and Zhang, Ruyi and Gao, Jiuhe and Wei, Wenchao and Jiang, Lanping and Li, Tianhui and Ding, Yanqiang and Wang, Luyao and Lin, Yufeng and Wong, Chi Chun and Yu, Jun},
  title = {Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {10},
  pages = {1885--1901.e10},
  doi = {10.1016/j.ccell.2025.07.012}
}
Kostenlos starten →